Zweig-DiMenna Associates’s CareDx CDNA Stock Holding History

Zweig-DiMenna Associates’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.1M	Sell	388,812 -1,443	-0.4%	-$31.4K	1.01%	38
2026 Q1	$6.77M	Sell	390,255 -288,745	-43%	-$5.47M	0.94%	37
2025 Q4	$12.8M	Buy	679,000 +104,000	+18%	+$1.74M	0.79%	41
2025 Q3	$8.36M	Buy	575,000 +348,400	+154%	+$4.97M	0.59%	59
2025 Q2	$4.43M	Buy	+226,600	New	+$4.03M	0.42%	65
2022 Q3	–	Sell	-301,474	Closed	-$6.48M	–	89
2022 Q2	$6.48M	Buy	301,474 +68,100	+29%	+$1.89M	1.23%	31
2022 Q1	$8.63M	Sell	233,374 -19,900	-8%	-$776K	1.15%	33
2021 Q4	$11.5M	Buy	253,274 +79,500	+46%	+$4.15M	0.93%	48
2021 Q3	$11M	Buy	173,774 +24,400	+16%	+$1.86M	0.76%	57
2021 Q2	$13.7M	Buy	149,374 +821	+0.6%	+$65.3K	0.82%	47
2021 Q1	$10.1M	Buy	148,553 +7,547	+5%	+$586K	0.7%	59
2020 Q4	$10.2M	Sell	141,006 -71,817	-34%	-$4.16M	0.65%	62
2020 Q3	$8.07M	Sell	212,823 -25,231	-11%	-$852K	0.55%	69
2020 Q2	$8.43M	Buy	+238,054	New	+$6.77M	0.89%	41

Other funds holding CDNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $38.8B AUM 41.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Zweig-DiMenna Associates's CDNA Position: Q2 2026 in Review

Zweig-DiMenna Associates reduced its CareDx (CDNA) stake by 0.37% in Q2 2026, selling an estimated $31.4K and leaving 388,812 shares worth $11.1M. The position accounts for 1.01% of the portfolio, ranked #38.

Zweig-DiMenna Associates first reported a position in CDNA in Q2 2020 and has held it in 14 quarters since. The position peaked at $13.7M in Q2 2021. 227 funds tracked by Wall St. Rank hold CDNA as of Q2 2026.

Zweig-DiMenna Associates held 388,812 shares of CareDx worth $11.1M as of Q2 2026.
Zweig-DiMenna Associates sold 1,443 CareDx shares in Q2 2026, an estimated $31.4K.
CareDx made up 1.01% of Zweig-DiMenna Associates's portfolio in Q2 2026, its #38 holding.
Zweig-DiMenna Associates first reported a position in CareDx in Q2 2020 and has held it in 14 quarters since.
Zweig-DiMenna Associates's CareDx position peaked at $13.7M in Q2 2021.
227 funds tracked by Wall St. Rank held CareDx as of Q2 2026.

Based on Zweig-DiMenna Associates's 13F filing for Q2 2026, filed 13 Aug 2026.